Beijing Strong Biotechnologies, Inc.
Shenzhen Stock Exchange 300406.SZ
Beijing Strong Biotechnologies, Inc. Operating Income Margin for the year ending December 31, 2023: 34.10%
Beijing Strong Biotechnologies, Inc. Operating Income Margin is 34.10% for the year ending December 31, 2023, a 13.11% change year over year. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.
-
Beijing Strong Biotechnologies, Inc. Operating Income Margin for the year ending December 31, 2022 was 30.15%, a -10.02% change year over year.
-
Beijing Strong Biotechnologies, Inc. Operating Income Margin for the year ending December 31, 2021 was 33.50%, a 85.67% change year over year.
-
Beijing Strong Biotechnologies, Inc. Operating Income Margin for the year ending December 31, 2020 was 18.05%, a -59.83% change year over year.
-
Beijing Strong Biotechnologies, Inc. Operating Income Margin for the year ending December 31, 2019 was 44.92%, a 0.15% change year over year.
Key data
| Date | Operating Income Margin | EBT Margin | Net Income Margin | EBITDA Margin |
|---|
Market news
Loading...
Don’t Miss A Beat
Shenzhen Stock Exchange: 300406.SZ
| CEO | Mr. Xi Liu |
| IPO Date | Oct. 30, 2014 |
| Location | China |
| Headquarters | Kuang Yi Building |
| Employees | 1,094 |
| Sector | Healthcare |
| Industries | |
Description
Beijing Strong Biotechnologies, Inc. provides in-vitro diagnostics products and services in the People's Republic of China and internationally. It offers clinical biochemistry products, such as reagents and automatic biochemistry analyzers; coagulation products, including reagents and automated coagulation analyzers; and serology products comprising blood type test cards and automated blood grouping analyzers. The company was founded in 2001 and is headquartered in Beijing, the People's Republic of China.
Key trends
Past 5 years
StockViz Staff
February 4, 2025
Any question? Send us an email